@Article{096504017X14874337324615,
AUTHOR = {Li-Kun Yang, Jie Zhu, Yu-Hua Chen, Dong-Liang Wang, Hua Li, Liang-Jun Zhang, Jing-Ru Zhou, Wei Liu},
TITLE = {Knockdown of Angiopoietin-Like Protein 2 Inhibits Proliferation and Invasion  in Glioma Cells via Suppressing the ERK/MAPK Signaling Pathway},
JOURNAL = {Oncology Research},
VOLUME = {25},
YEAR = {2017},
NUMBER = {8},
PAGES = {1349--1355},
URL = {http://www.techscience.com/or/v25n8/56919},
ISSN = {1555-3906},
ABSTRACT = {Angiopoietin-like protein 2 (ANGPTL2), a member of the glycoprotein family, is mainly secreted by adipose tissues under normal conditions. Recently, ANGPTL2 has been found to be upregulated in some types 
of cancers and is considered to be a tumor promoter. However, the functional significance of ANGPTL2 in 
glioma has not yet been elucidated. In this study, we investigated the specific role of ANGPTL2 in glioma. The 
results showed that ANGPTL2 was highly expressed in glioma tissues and cell lines. Knockdown of ANGPTL2 
reduced the proliferative and invasive abilities of glioma cells. Moreover, the tumorigenesis assay showed that 
ANGPTL2 knockdown inhibited glioma tumor growth in vivo. We also found that ANGPTL2 knockdown 
decreased the protein levels of p-ERK1/2 in glioma cells and thus blocked the activity of the ERK/MAPK signaling pathway. Taken together, our study provided the first evidence that ANGPTL2 played an oncogenic role 
in glioma development and might be considered as a new therapeutic target for glioma treatment.},
DOI = {10.3727/096504017X14874337324615}
}